Table 2 Post-transplantation outcomes for all NKTCL patients.

From: Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis

Outcomes

Evaluable patients (N)

Probability (95% CI)

Acute GVHD Grade II-IV

112

 

 100 days

 

18.8% (12.1–26.5%)

Chronic GVHD

124

 

 1 year

 

29.6% (21.7–37.9%)

 2 years

 

34.5% (25.9–43.1%)

 3 years

 

34.5% (25.9–43.1%)

Relapse incidence

130

 

 1 year

 

29.6% (21.9–37.6%)

 2 years

 

33.0% (24.9–41.3%)

 3 years

 

34.1% (25.8–42.4%)

Non-relapse mortality

130

 

 1 year

 

14.8% (9.3–21.5%)

 2 years

 

17.3% (11.3–24.5%)

 3 years

 

17.3% (11.3–24.5%)

Progression-free survival

135

 

 1 year

 

55.6% (46.6–63.7%)

 3 years

 

48.6% (39.5–57%)

 5 years

 

48.6% (39.5–57%)

Overall survival

135

 

 1 year

 

66.9% (58.1–74.2%)

 3 years

 

55.6% (46.5–63.8%)

 5 years

 

52.9% (43.4–61.5%)

  1. CI confidence interval, GVHD graft-versus-host disease.
Back to article page